Treats myasthenia gravis. ANDA 216512, held by Msn. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 216512 (Pyridostigmine Bromide), held by Msn, was first approved by FDA on Sep 21, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATION: Pyridostigmine bromide oral solution is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 21, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG/5ML · syrup;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters